September 27, 2025 • 6 mins
# Navigating Ozempic: Breakthrough Oral Semaglutide Pill Shows Promise for Weight Loss Without Needles
Discover the latest groundbreaking developments in GLP-1 medications as our podcast examines the game-changing OASIS-4 clinical trial results published in The New England Journal of Medicine. This episode explores how the new oral form of semaglutide achieved impressive 14-16% weight loss results, rivaling injectable versions like Ozempic and Wegovy. We also cover surprising new research revealing the pancreas's natural GLP-1 production abilities, upcoming patent expirations that could dramatically reduce medication costs, and emerging evidence that semaglutide may protect against diabetic eye disease. Stay informed about regulatory changes affecting compounded versions and learn what these advancements mean for obesity treatment, metabolic health, and diabetes management. Perfect for healthcare providers, patients, and anyone interested in the evolving landscape of weight management medications.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Discover the latest groundbreaking developments in GLP-1 medications as our podcast examines the game-changing OASIS-4 clinical trial results published in The New England Journal of Medicine. This episode explores how the new oral form of semaglutide achieved impressive 14-16% weight loss results, rivaling injectable versions like Ozempic and Wegovy. We also cover surprising new research revealing the pancreas's natural GLP-1 production abilities, upcoming patent expirations that could dramatically reduce medication costs, and emerging evidence that semaglutide may protect against diabetic eye disease. Stay informed about regulatory changes affecting compounded versions and learn what these advancements mean for obesity treatment, metabolic health, and diabetes management. Perfect for healthcare providers, patients, and anyone interested in the evolving landscape of weight management medications.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
We'll come back to Navigating a Zempic, where we cut
through the latest news and research on a zepic and
its evolving role in medicine, wellness, and society. Over the
last three days, there have been major headlines and advancements
you need to know, from clinical breakthroughs to surprising scientific discoveries.
Let us jump right in. One of the biggest stories
(00:20):
comes from the New England Journal of Medicine, which just
published the results of the Oasis four clinical trial on
September twenty fourth. This trial investigated a new pill form
of ozempic, also known as oral semiglutide, for people living
with overweight or obesity. The trial enrolled hundreds of participants
across several countries, giving half of them a daily pill
(00:41):
of twenty five milligrams semagluetide and the other half of placebo,
along were lifestyle counseling. After sixty four weeks, those who
took the active pill lost, on average nearly fourteen per
cent of their body weight, compared to just two percent
in the placebo group. When trial participants were analyzed strictly
on those who stuck to the plan, average weight loss
(01:02):
was an astonishing sixteen point six percent. Note This result
closely matches the efficacy seen with injectable ozempic, but now
as a needle free alternative. Reporting from Cytec Daily and
Drugs dot Com both highlight expert commentary that oral semaglutide
might offer significant new options for patients with a safety
(01:22):
and tolerability profile in line with existing GLP one treatments.
This news has big implications for listeners who have been
hesitant to start injectable weight loss medicines or who currently
manage obesity or related health issues without medication. The prospect
of an effective pill opens up new possibilities. Oral semagluetide
(01:44):
is currently under review with the Food and Drug Administration,
with approval possible by the end of this year. Novo Nordisk,
the company behind ozempican Wagovi, has already begun massive an
act of facturing preparations so that, if approved, pill production
for weight management in the United States will be entirely domestic.
(02:05):
Experts are careful to note that this particular study did
not include people living the diabetes, so it does not
generalize to all patients. Yet, there is also interest in
how folks maintain weight loss and other health benefits after
stopping the drug, something future research will aim to clarify.
While much of the media coverage is focusing on the
weight loss aspect, cardiometabolic health also saw improvements in this trial.
(02:30):
Researchers documented meaningful boosts in physical function and multiple cardiovascular
risk factors among those using the oral pill. These wider
benefits are prompting hope that if approved, oral ozepic may
do more than support weight loss, it could positively affect
overall quality of life and long term health outcomes for
millions switching gears. A surprising scientific development came out on
(02:54):
September twenty first. Science Daily reports that researchers have uncovered
a hidden ability within your own pancreas to naturally produce
GLP one, the hormone mimicked by ozempic and similar medications. Previously,
it was believed that only the intestines generated GLP one. Now,
scientists have found that alpha cells in the pancreas can
(03:16):
make GLP one as well as lukagan, which is important
in bloodshed a regulation. This discovery might help explain why
some people respond differently to GLP one therapies, and could
suggest new ways of managing diabetes. The backup system inside
the pancreas could allow patients bodies to compensate if hormonevel's
drop or treatments change. This opens new doors in understanding
(03:38):
both the biology of GLP one and how future therapies
could be personalized. News about copycat or compounded versions of
ozempic continues to swell as regulatory challenges persist. According to
Business Insider, online pharmacies have found loopholes to keep selling cheaper,
off brand semaglutide products despite e titened Food and Drug
(03:59):
administs stration rules meant to restrict such sales. These copycat drugs,
often marketed as alternatives to ozempic and monjaro, remain widely
available despite concerns around safety, quality and proper dosing. The
regulatory landscape is shifting, but as demand for affordable solutions grows,
so does the ingenuity of online sellers and compounding pharmacies.
(04:22):
Experts urge listeners to be cautious and consult with your
health care provider before considering any generic or compounded options,
especially as oversight and legality may differ from month to month.
Looking ahead, the legal and economic landscape is about to
shift further. The Independent notes that the global patent held
by Novo Nordisk for Ozepic and wagovi is set to
(04:43):
expire in parts of the world starting early next year
twenty twenty six. This expiration could open the door for
competitors and generic manufacturers to step in with their own
own label injections, some potentially costing as little as twenty
pounds per month. For people who have struggled with lost
or access to branded weight loss treatments, this offers hope
for wider availability. The anticipated influx of generic options might
(05:07):
further disrupt the market, pushing prices lower and helping many
more people benefit from GLP one therapy, provided quality standards
are enforced. Beyond weight management, there are new hints about
benefits for diabetic complications. Medical News Today reported on September
twenty third that semaglutide, the active ingredient in a zepic,
(05:27):
may help protect against blindness caused by diabetes related eye disease,
specifically retinopathy. The research is still unfolding, but it points
to a protective effect on the retina, the area at
the back of the eye most vulnerable in advanced diabetes.
This could make ozepic not just a tool for weight
loss or glucose control, but also for defending sight among
(05:48):
high risk populations. If confirmed in further trials, this added
benefit could profoundly affect diabetes care guidelines. Interest and dose
escalation also remains strong. A study of it by Healthline
We'll come back to Navigating a Zempic, where we cut
through the latest news and research on a zepic and
its evolving role in medicine, wellness, and society. Over the
last three days, there have been major headlines and advancements
you need to know, from clinical breakthroughs to surprising scientific discoveries.
Let us jump right in. One of the biggest stories
(00:20):
comes from the New England Journal of Medicine, which just
published the results of the Oasis four clinical trial on
September twenty fourth. This trial investigated a new pill form
of ozempic, also known as oral semiglutide, for people living
with overweight or obesity. The trial enrolled hundreds of participants
across several countries, giving half of them a daily pill
(00:41):
of twenty five milligrams semagluetide and the other half of placebo,
along were lifestyle counseling. After sixty four weeks, those who
took the active pill lost, on average nearly fourteen per
cent of their body weight, compared to just two percent
in the placebo group. When trial participants were analyzed strictly
on those who stuck to the plan, average weight loss
(01:02):
was an astonishing sixteen point six percent. Note This result
closely matches the efficacy seen with injectable ozempic, but now
as a needle free alternative. Reporting from Cytec Daily and
Drugs dot Com both highlight expert commentary that oral semaglutide
might offer significant new options for patients with a safety
(01:22):
and tolerability profile in line with existing GLP one treatments.
This news has big implications for listeners who have been
hesitant to start injectable weight loss medicines or who currently
manage obesity or related health issues without medication. The prospect
of an effective pill opens up new possibilities. Oral semagluetide
(01:44):
is currently under review with the Food and Drug Administration,
with approval possible by the end of this year. Novo Nordisk,
the company behind ozempican Wagovi, has already begun massive an
act of facturing preparations so that, if approved, pill production
for weight management in the United States will be entirely domestic.
(02:05):
Experts are careful to note that this particular study did
not include people living the diabetes, so it does not
generalize to all patients. Yet, there is also interest in
how folks maintain weight loss and other health benefits after
stopping the drug, something future research will aim to clarify.
While much of the media coverage is focusing on the
weight loss aspect, cardiometabolic health also saw improvements in this trial.
(02:30):
Researchers documented meaningful boosts in physical function and multiple cardiovascular
risk factors among those using the oral pill. These wider
benefits are prompting hope that if approved, oral ozepic may
do more than support weight loss, it could positively affect
overall quality of life and long term health outcomes for
millions switching gears. A surprising scientific development came out on
(02:54):
September twenty first. Science Daily reports that researchers have uncovered
a hidden ability within your own pancreas to naturally produce
GLP one, the hormone mimicked by ozempic and similar medications. Previously,
it was believed that only the intestines generated GLP one. Now,
scientists have found that alpha cells in the pancreas can
(03:16):
make GLP one as well as lukagan, which is important
in bloodshed a regulation. This discovery might help explain why
some people respond differently to GLP one therapies, and could
suggest new ways of managing diabetes. The backup system inside
the pancreas could allow patients bodies to compensate if hormonevel's
drop or treatments change. This opens new doors in understanding
(03:38):
both the biology of GLP one and how future therapies
could be personalized. News about copycat or compounded versions of
ozempic continues to swell as regulatory challenges persist. According to
Business Insider, online pharmacies have found loopholes to keep selling cheaper,
off brand semaglutide products despite e titened Food and Drug
(03:59):
administs stration rules meant to restrict such sales. These copycat drugs,
often marketed as alternatives to ozempic and monjaro, remain widely
available despite concerns around safety, quality and proper dosing. The
regulatory landscape is shifting, but as demand for affordable solutions grows,
so does the ingenuity of online sellers and compounding pharmacies.
(04:22):
Experts urge listeners to be cautious and consult with your
health care provider before considering any generic or compounded options,
especially as oversight and legality may differ from month to month.
Looking ahead, the legal and economic landscape is about to
shift further. The Independent notes that the global patent held
by Novo Nordisk for Ozepic and wagovi is set to
(04:43):
expire in parts of the world starting early next year
twenty twenty six. This expiration could open the door for
competitors and generic manufacturers to step in with their own
own label injections, some potentially costing as little as twenty
pounds per month. For people who have struggled with lost
or access to branded weight loss treatments, this offers hope
for wider availability. The anticipated influx of generic options might
(05:07):
further disrupt the market, pushing prices lower and helping many
more people benefit from GLP one therapy, provided quality standards
are enforced. Beyond weight management, there are new hints about
benefits for diabetic complications. Medical News Today reported on September
twenty third that semaglutide, the active ingredient in a zepic,
(05:27):
may help protect against blindness caused by diabetes related eye disease,
specifically retinopathy. The research is still unfolding, but it points
to a protective effect on the retina, the area at
the back of the eye most vulnerable in advanced diabetes.
This could make ozepic not just a tool for weight
loss or glucose control, but also for defending sight among
(05:48):
high risk populations. If confirmed in further trials, this added
benefit could profoundly affect diabetes care guidelines. Interest and dose
escalation also remains strong. A study of it by Healthline
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Cardiac Cowboys
The heart was always off-limits to surgeons. Cutting into it spelled instant death for the patient. That is, until a ragtag group of doctors scattered across the Midwest and Texas decided to throw out the rule book. Working in makeshift laboratories and home garages, using medical devices made from scavenged machine parts and beer tubes, these men and women invented the field of open heart surgery. Odds are, someone you know is alive because of them. So why has history left them behind? Presented by Chris Pine, CARDIAC COWBOYS tells the gripping true story behind the birth of heart surgery, and the young, Greatest Generation doctors who made it happen. For years, they competed and feuded, racing to be the first, the best, and the most prolific. Some appeared on the cover of Time Magazine, operated on kings and advised presidents. Others ended up disgraced, penniless, and convicted of felonies. Together, they ignited a revolution in medicine, and changed the world.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.